NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization217.93 mln
Float6.92 mln
Earnings Date11/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-5.3
Highly reliable
1-Year Forecast
90.50
Transformational upside
Relative Strength
96
/ 100
Top performer
Debt / Equity
1.33
Elevated leverage
Pre-Tax Margin
-434%
Severely loss-making
Business Description
Cue Biopharma is a Boston-based company focused on developing injectable medicines that work with the body's immune system to treat cancer and autoimmune diseases. Its most advanced treatments target HPV-related head and neck cancers as well as certain colorectal, gastric, ovarian, and pancreatic cancers, with several programs currently in clinical trials. The company also has earlier-stage treatments in development aimed at reducing harmful immune responses in autoimmune conditions. Cue Biopharma works alongside partners such as LG Chem and Ono Pharmaceutical to advance and commercialize its pipeline.
